Providing equitable access to low-cost, rapid health diagnostic solutions globally.
Utilizing the newest A.I modelling technology to deliver results fast to the patient. Upload scans onto our platform for rapid results and share a copy of the scans directly with the patient.
Learn MoreAn adaptable recombinant protein system. Enables rapid, low-cost, scalable diagnostic tests to be produced. Stand-alone diagnostic tests are visible to the naked eye with rapid results.
Learn MoreAn adaptable system using recombinant proteins enabling rapid diagnostics with low cost solution
A rapid diagnostic antigen test with a highly scalable, low cost approach.
An easy to read, portable platform, with the ability to be delivered at a very low cost.
Patented technologies utilized for diagnostic platform.
EzeChek is designing a path to deliver top tier diagnostics imaging results. With the COVID-19 pandemic continuing to take its toll on the world, we recognized the need for better diagnostics platforms to manage the unrelenting need of humanity today.
A goal of providing top tier diagnostics imaging recognition to the world, with scalability and affordability in mind. In addition to this, we are leading the way to develop low cost scalable diagnostics tests to the developing world.
Learn moreDelivering rapid responses to people around the world.
Contact UsWe are an impact driven organization interested in increasing accessibility to high quality healthcare in developing nations. The need for highly specialized technology with scalability in mind, remains evident as the ever increasing demand of diagnostics around the world continues. Artificial Intelligence is required to help alieviate the pressures faced around the world.
The pandemic has demonstrated humanity's reliance on scalable and affordable technologies when it comes to diagnostics. We are paving the way for a new type of diagnostics for the developing world. As of now, there are not enough trained medical professionals in the developing world to manage all of the scans being taken. In addition to this, it is too costly as of yet.